MCID: APH002
MIFTS: 55

Aphasia

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 11 52 53 5 41 43 14 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:0060046
MeSH 43 D001037
UMLS 71 C0003537

Summaries for Aphasia

MedlinePlus: 41 What is aphasia? Aphasia is a language disorder that makes it hard for you to read, write, and say what you mean to say. Sometimes it makes it hard to understand what other people are saying, too. Aphasia is not a disease. It's a symptom of damage to the parts of the brain that control language. The signs of aphasia depend on which part of the brain is damaged. There are four main types of aphasia: Expressive aphasia is when you know what you want to say, but you have trouble saying or writing your thoughts. Receptive aphasia affects your ability to read and understand speech. You can hear what people say or see words on a page, but you have trouble making sense of what they mean. Global aphasia is the loss of almost all language ability. You can't speak, understand speech, read, or write. Anomic or amnesia aphasia is when you have trouble using the right words for certain things, people, places or events. In some cases, aphasia may get better on its own. But it can be a long-term condition. There's no cure, but treatment may help improve language skills. What causes aphasia? Aphasia happens from damage to one or more parts of the brain involved with language. The damage may be from: Stroke, which is the most common cause of aphasia Brain tumor Brain infection or inflammation Brain injury Other brain disorders or neurologic diseases that affect the brain and get worse over time, such as dementia Who is more likely to develop aphasia? Anyone can have aphasia at any age, but most people with aphasia are middle-aged or older. Most aphasia happens suddenly from a stroke or brain injury. Aphasia from a brain tumor or other brain disorder may develop slowly over time. How is aphasia diagnosed? If a health care provider sees signs of aphasia, the provider will usually: Test the person's ability to understand language and speech. This includes asking questions and checking to see if the person can follow simple commands. Order an imaging scan to see if there's a brain injury and what part of the brain is damaged. Possible tests include: MRI CT scan If imaging shows signs of aphasia, more tests may be needed. These tests measure how much the brain damage has affected the ability to talk, read, write, and understand. In most cases, the tests are done by a speech-language pathologist or speech therapist (a specialist who treats speech and communication disorders). What are the treatments for aphasia? Some people fully recover from aphasia without treatment. But most people should begin speech-language therapy to treat aphasia as soon as possible. Treatment may be one-on-one with a speech therapist or in a group. Therapy using a computer may also be helpful. The specific therapy depends on the type of language loss that a person has. It may include exercises in reading, writing, following directions, and repeating what the therapist says. Therapy may also include learning how to communicate with gestures, pictures, smartphones, or other electronic devices. Family participation may be an important part of speech therapy. Family members can learn to help with recovery in many ways, such as: Using simpler language Including the person with aphasia in conversations Repeating or writing down key words to help communicate more clearly Language abilities may continue to improve over many years. In general, people recover their ability to understand language more fully than their ability to speak. How much a person recovers depends on many things, including: What caused the brain injury What part of the brain was hurt How badly and how much of the brain was hurt The age and health of the person Can aphasia be prevented? You can help prevent aphasia by: Making heart-healthy lifestyle changes to lower your chance of having: A stroke Heart disease Vascular disease (problems with your blood vessels) Protecting your brain from injury: Wearing the right helmet for sports safety, such as when riding a bike Taking action to prevent falls Always wearing your seatbelt and driving safely NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary: Aphasia is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and progressive non-fluent aphasia, and has symptoms including tremor, fever and back pain. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Signal Transduction and Alzheimer's disease and miRNA effects. The drugs Levodopa and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and bone marrow, and related phenotypes are nervous system and no phenotypic analysis

NINDS: 52 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Individuals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

Disease Ontology: 11 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

Wikipedia: 75 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 619)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.3 PRNP MAPT GRN
2 progressive non-fluent aphasia 32.8 TBK1 PSEN1 MAPT GRN C9orf72
3 nominal aphasia 32.6 TARDBP SNCA PSEN1 MAPT GRN C9orf72
4 apraxia 32.3 PSEN1 MAPT FOXP2
5 gerstmann syndrome 32.2 TARDBP PSEN1 PRNP MAPT APOE
6 frontotemporal dementia and/or amyotrophic lateral sclerosis 7 31.8 TARDBP MAPT GRN
7 agraphia 31.8 TARDBP PRNP MAPT GRN C9orf72 APOE
8 inclusion body myopathy with paget disease of bone and frontotemporal dementia 31.8 TARDBP OPTN MAPT GRN C9orf72
9 cerebrovascular disease 31.6 MAPT BDNF APP APOE
10 corticobasal degeneration 31.3 TARDBP MAPT
11 frontotemporal dementia 31.2 TOMM40 TBK1 TARDBP SNCB SNCA PSEN1
12 supranuclear palsy, progressive, 1 31.1 TARDBP SNCA PSEN1 PRNP NEFL MAPT
13 mutism 31.1 PRNP MAPT GRN C9orf72
14 speech disorder 31.1 TARDBP MAPT GRN GRIN2A FOXP2 C9orf72
15 pick disease of brain 31.1 TARDBP SNCB SNCA PSEN1 PRNP OPTN
16 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 31.0 TBK1 TARDBP SNCA PSEN1 OPTN NEFL
17 dysgraphia 31.0 TARDBP MAPT GRN C9orf72
18 alexia 31.0 TARDBP PSEN1 PRNP MAPT GRN C9orf72
19 auditory agnosia 31.0 GRIN2A FOXP2
20 echolalia 30.9 MAPT GRN FOXP2 C9orf72
21 anosognosia 30.8 PSEN1 MAPT C9orf72 APOE
22 amnestic disorder 30.8 PSEN1 MAPT GRIN2A BDNF APP APOE
23 amyloidosis 30.8 SNCA PSEN1 PRNP MAPT APP APOE
24 speech and communication disorders 30.7 TARDBP SNCA PSEN1 PRNP NEFL MAPT
25 tremor 30.7 SNCA MAPT LRRK2
26 lateral sclerosis 30.7 TBK1 TARDBP OPTN NEFL C9orf72
27 amusia 30.7 GRN FOXP2
28 psychotic disorder 30.6 PSEN1 GRIN2A BDNF APP APOE
29 associative agnosia 30.6 TARDBP MAPT GRN C9orf72
30 ideomotor apraxia 30.5 TARDBP SNCA PSEN1 PRNP MAPT GRN
31 prosopagnosia 30.5 TARDBP MAPT GRN C9orf72
32 learning disability 30.5 GRIN2A FOXP2 BDNF
33 parkinsonism 30.5 TARDBP SNCB SNCA PSEN1 MAPT LRRK2
34 finger agnosia 30.5 MAPT GRN
35 visual agnosia 30.5 PSEN1 PRNP MAPT GRN C9orf72 APP
36 down syndrome 30.4 PSEN1 MAPT BDNF APP APOE
37 mild cognitive impairment 30.3 TOMM40 SNCA PSEN1 NEFL MAPT BDNF
38 cerebral degeneration 30.3 SNCA NEFL MAPT L1CAM APP APOE
39 anxiety 30.3 SNCA GRIN2A BDNF APP APOE
40 creutzfeldt-jakob disease 30.3 TARDBP SNCA PSEN1 PRNP MAPT LRRK2
41 sleep disorder 30.2 SNCA LRRK2 BDNF APOE
42 prion disease 30.2 SNCA PSEN1 PRNP MAPT APP
43 dystonia 30.1 SNCA LRRK2 C9orf72 BDNF APOE
44 motor neuron disease 30.1 TBK1 TARDBP SNCA OPTN NEFL MAPT
45 autism spectrum disorder 30.1 SNCA NEFL GRIN2A FOXP2 CNKSR2 BDNF
46 dementia 30.1 TBK1 TARDBP SNCB SNCA PSEN1 PRNP
47 writing disorder 30.1 TARDBP PRNP MAPT GRN C9orf72
48 alzheimer disease, familial, 1 30.0 TOMM40 TARDBP SNCB SNCA PSEN1 PRNP
49 cerebral amyloid angiopathy, cst3-related 30.0 TARDBP SNCA PSEN1 PRNP MAPT APP
50 gait apraxia 30.0 PRNP GRN

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


tremor; fever; back pain; dyspnea; vertigo; cachexia; headache; syncope; scanning speech; cyanosis; edema; pain; chronic pain; sciatica; sore throat; icterus; seizures; signs and symptoms; signs and symptoms, digestive; other symbolic dysfunction; hot flushes; vertigo/dizziness; sleeplessness; other symptoms involving head and neck; swelling, mass, or lump in head and neck; aprosodia; aphasic; symptoms involving head and neck; other and unspecified speech disturbances; other speech disturbances; central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.44 APOE APP BDNF C9orf72 FOXP2 GRIN2A
2 no phenotypic analysis MP:0003012 10.4 APOE APP BDNF C9orf72 FOXP2 GRN
3 homeostasis/metabolism MP:0005376 10.37 APOE APP BDNF C9orf72 FOXP2 GRN
4 behavior/neurological MP:0005386 10.36 APOE APP BDNF C9orf72 CNKSR2 FOXP2
5 growth/size/body region MP:0005378 10.29 APOE APP BDNF C9orf72 FOXP2 GRN
6 cellular MP:0005384 10.27 APOE APP BDNF C9orf72 FOXP2 GRN
7 immune system MP:0005387 10.22 APOE APP C9orf72 FOXP2 GRN LRRK2
8 normal MP:0002873 10.19 APP BDNF LRRK2 MAPT NEFL PRNP
9 skeleton MP:0005390 10.07 APOE APP CNKSR2 L1CAM LRRK2 PRNP
10 vision/eye MP:0005391 10.06 APOE APP BDNF FOXP2 GRN L1CAM
11 hematopoietic system MP:0005397 9.97 APOE APP C9orf72 FOXP2 GRN LRRK2
12 mortality/aging MP:0010768 9.89 APOE APP BDNF C9orf72 FOXP2 GRN
13 taste/olfaction MP:0005394 9.56 APOE BDNF MAPT SNCA
14 integument MP:0010771 9.44 APOE APP BDNF C9orf72 GRIN2A GRN

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
2
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
5
Dexetimide Withdrawn Phase 4 21888-98-2 30843
6
Corticosterone Experimental Phase 4 50-22-6 5753
7 Dopamine agonists Phase 4
8 Nootropic Agents Phase 4
9 Cholinesterase Inhibitors Phase 4
10 Cholinergic Agents Phase 4
11 Serotonin Uptake Inhibitors Phase 4
12 Excitatory Amino Acid Antagonists Phase 4
13 Fluorodeoxyglucose F18 Phase 4
14 Anti-Inflammatory Agents Phase 4
15
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
16
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
19
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
20
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
21
Miglustat Approved Phase 3 72599-27-0 51634
22 Orange Approved Phase 3
23 Carbidopa, levodopa drug combination Phase 2, Phase 3
24 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
25 Hypoglycemic Agents Phase 3
26 Cardiac Glycosides Phase 3
27 Anti-Retroviral Agents Phase 3
28 Anti-HIV Agents Phase 3
29 Glycoside Hydrolase Inhibitors Phase 3
30
D-Leucine Experimental, Investigational, Nutraceutical Phase 3 328-38-1, 61-90-5 439524 6106
31
Galantamine Approved Phase 2 357-70-0, 1953-04-4 9651
32
Dextroamphetamine Approved, Illicit, Investigational Phase 2 51-64-9, 300-62-9 5826 3007
33
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
34
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 581 12035
35
Tolcapone Approved, Withdrawn Phase 2 134308-13-7 4659569
36
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
37
Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
38
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 4894 5755
39
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5 1875
40
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 4159 6741
41
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
42
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
43
Rituximab Approved Phase 1, Phase 2 174722-31-7
44
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
45
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
46
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
47
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
48
Lithium carbonate Approved Phase 2 554-13-2
49
Sulfamethazine Approved, Investigational, Vet_approved Phase 1, Phase 2 57-68-1 5327
50
Rotigotine Approved Phase 2 99755-59-6, 92206-54-7 57537 59227

Interventional clinical trials:

(show top 50) (show all 435)
# Name Status NCT ID Phase Drugs
1 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
2 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia) Completed NCT00102869 Phase 4 levodopa
3 Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. Completed NCT00196690 Phase 4 Donepezil
4 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Completed NCT00640198 Phase 4 memantine;placebo
5 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
8 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
9 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
10 Effects of Repetitive Magnetic Transcranial Stimulation of Low Frequency on Speech Production in Patients With Non-fluent Aphasia Post-ischemic Stroke Unknown status NCT02241213 Phase 3
11 Improvement of Aphasia After Stroke by Intensive Training and Transcranial Direct Current Stimulation Unknown status NCT00822068 Phase 2, Phase 3
12 Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia Completed NCT00903266 Phase 3
13 Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
14 Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia Completed NCT04134416 Phase 3 Donepezil
15 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
16 Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion Completed NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
17 A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
18 An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
19 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
20 A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene Recruiting NCT04374136 Phase 3 AL001;Placebo;Open label - AL001
21 Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC) Recruiting NCT04860960 Phase 3 Hydroxypropyl-beta-cyclodextrin;Placebo
22 Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study Recruiting NCT05163288 Phase 3 N-Acetyl-L-Leucine
23 Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy Terminated NCT01277575 Phase 3
24 An Open-Label, Extension Study of the Effects of LMTM in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 LMTM
25 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
26 Targeted Transcranial Electrotherapy for Stroke Rehabilitation - Exploratory Trial on Aphasia Unknown status NCT02540109 Phase 2
27 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Unknown status NCT01221779 Phase 2
28 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
29 Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes Completed NCT01686373 Phase 2
30 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
31 Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase Completed NCT02514044 Phase 2 Dexedrine;Placebo
32 Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
33 A Parallel, Virtual, Randomized Trial of PCT for Speech, Language, and Cognitive Intervention in Stroke Patients Completed NCT04488029 Phase 2
34 Open-label, Exploratory Study of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Naming and Verbal Fluency in Patients With Alzheimer's Disease With Functional Imaging Correlates Completed NCT00814697 Phase 2
35 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Completed NCT02676843 Phase 2 18F-AV-1451
36 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Completed NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
37 A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
38 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
39 Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor Completed NCT00730314 Phase 1, Phase 2
40 An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex Completed NCT00416169 Phase 2 galantamine hydrobromide
41 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
42 Investigation of the Dopamine System in Frontotemporal Dementia Completed NCT00604591 Phase 2 Tolcapone;Placebo
43 Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
44 A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes Completed NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
45 Speech Entrainment for Aphasia Recovery Recruiting NCT04364854 Phase 2
46 Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Recruiting NCT05615922 Phase 2
47 Treating Primary Progressive Aphasia (PPA) and Elucidating Neurodegeneration in the Language Network Using Transcranial Direct Current Stimulation (tDCS) Recruiting NCT04046991 Phase 2
48 Escitalopram and Language Intervention for Subacute Aphasia (ELISA) Recruiting NCT03843463 Phase 2 Escitalopram 10mg;Placebo
49 A Phase II, Randomized Blinded Study of the Effects of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the Treatment of Chronic Aphasia Recruiting NCT03651700 Phase 2
50 The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy Recruiting NCT04309253 Phase 2 PMPBB3;AV45

Search NIH Clinical Center for Aphasia

Cochrane evidence based reviews: aphasia

Genetic Tests for Aphasia

Anatomical Context for Aphasia

Organs/tissues related to Aphasia:

MalaCards : Brain, Heart, Bone Marrow, Prefrontal Cortex, Cortex, Temporal Lobe, Eye

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 14769)
# Title Authors PMID Year
1
Attention to attention in aphasia - elucidating impairment patterns, modality differences and neural correlates. 62 41
36336090 2022
2
Can the resource reduction hypothesis explain sentence processing in aphasia? A visual world study in German. 62 41
36435153 2022
3
Remote versus face-to-face neuropsychological testing for dementia research: a comparative study in people with Alzheimer's disease, frontotemporal dementia and healthy older individuals. 62 41
36428012 2022
4
Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia. 53 62
20400120 2010
5
Expanding the phenotypic spectrum of L1CAM-associated disease. 53 62
16650080 2006
6
First case of L1CAM gene mutation identified in MASA syndrome in Asia. 53 62
15904436 2005
7
A silent mutation, C924T (G308G), in the L1CAM gene results in X linked hydrocephalus (HSAS). 53 62
9643285 1998
8
Identification of novel L1CAM mutations using fluorescence-assisted mismatch analysis. 53 62
9744477 1998
9
L1CAM mutation in a Japanese family with X-linked hydrocephalus: a study for genetic counseling. 53 62
9440802 1997
10
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. 62
36386035 2023
11
Constrained spherical deconvolution -based tractography of major language tracts reveals post-stroke bilateral white matter changes correlated to aphasia. 62
36252694 2023
12
Massive MCA stroke requiring alteplase followed by thrombectomy in a 34-year-old female with alport syndrome. 62
36270957 2023
13
Neural Correlates of Naturally Occurring Speech Errors during Picture Naming in Healthy Participants. 62
36306259 2022
14
Endoscopic transcortical expanded transforaminal transvenous transchoroidal approach to third ventricle lesion resection using an endoport. 62
36343500 2022
15
Temporal Overlap Between Gestures and Speech in Poststroke Aphasia: Is There a Compensatory Effect? 62
36455133 2022
16
Outcomes of an interprofessional intensive comprehensive aphasia program's first five years. 62
34698621 2022
17
Intensive Social Interaction for Treatment of Poststroke Depression in Subacute Aphasia: The CONNECT Trial. 62
36124755 2022
18
Association between aphasia and risk of dementia after stroke. 62
36283235 2022
19
Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature. 62
35963603 2022
20
People with aphasia share their views on self-management and the role of technology to support self-management of aphasia. 62
34657536 2022
21
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy. 62
36259217 2022
22
Author Correction: Determining levels of linguistic deficit by applying cluster analysis to the aphasia quotient of Western Aphasia Battery in post-stroke aphasia. 62
36456620 2022
23
Precision rehabilitation for aphasia by patient age, sex, aphasia severity, and time since stroke? A prespecified, systematic review-based, individual participant data, network, subgroup meta-analysis. 62
35422175 2022
24
Mapping lesion, structural disconnection, and functional disconnection to symptoms in semantic aphasia. 62
35786743 2022
25
What is Functional Communication? A Theoretical Framework for Real-World Communication Applied to Aphasia Rehabilitation. 62
35076868 2022
26
Preoperative function-specific connectome analysis predicts surgery-related aphasia after glioma resection. 62
35851513 2022
27
Penetrance of the V203I variant of the PRNP gene: report of a patient with stroke-like onset of Creutzfeld-Jacob Disease and review of published cases. 62
35167423 2022
28
Can we really 'read' art to see the changing brain? A review and empirical assessment of clinical case reports and published artworks for systematic evidence of quality and style changes linked to damage or neurodegenerative disease. 62
36179555 2022
29
Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles. 62
36001141 2022
30
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates. 62
36305960 2022
31
A carcinoid tumor of the middle ear masquerading as a glomus tympanicum presenting with temporal lobe hemorrhage in a 70-year-old woman: Case report and review of the literature. 62
35905789 2022
32
A case of V180I genetic mutation Creutzfeldt Jakob disease (CJD) with delusional misidentification as an initial symptom. 62
34965177 2022
33
Characterization of the logopenic variant of Primary Progressive Aphasia: A systematic review and meta-analysis. 62
36244629 2022
34
Aplastic or twig-like middle cerebral artery and cardiogenic cerebral embolism mimicking moyamoya disease with RNF213 polymorphism: A case report. 62
34913393 2022
35
Ruptured bilateral middle cerebral artery aneurysms diagnosed based on cerebral vasospasm-associated ischemic symptoms: A case report. 62
36176966 2022
36
Use and Perceived Effectiveness of Communication Modes Reported by Persons With Primary Progressive Aphasia. 62
36472941 2022
37
Primary progressive aphasia: ReADing the clinical GRANularity. 62
35710752 2022
38
Comprehensive qualitative characterization of linguistic performance profiles in primary progressive aphasia: a multivariate study with FDG-PET. 62
36195042 2022
39
Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech. 62
36166918 2022
40
The Wernicke conundrum revisited: evidence from connectome-based lesion-symptom mapping. 62
35727949 2022
41
Do age and language impairment affect speed of recognition for words with high and low closeness centrality within the phonological network? 62
36416187 2022
42
Enhanced Imaging and Language Assessments for Primary Progressive Aphasia. 62
35977838 2022
43
'Like going into a chocolate shop, blindfolded': What do people with primary progressive aphasia want from speech and language therapy? 62
36448629 2022
44
The affective, behavioural, and cognitive reactions to a diagnosis of Primary Progressive Aphasia: A qualitative descriptive study. 62
36054090 2022
45
Inter-hemispheric synchronicity and symmetry: The functional connectivity consequences of stroke and neurodegenerative disease. 62
36451366 2022
46
Primary progressive aphasia. 62
36416646 2022
47
Association of Regional Atrophy With Naming Decline in Primary Progressive Aphasia. 62
36319108 2022
48
The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution's experience and a systematic review of the literature. 62
36117185 2022
49
Dutch Diagnostic Instrument for Mild Aphasia (DIMA): standardisation and a first clinical application in two brain tumour patients. 62
35899484 2022
50
Longitudinal changes in behaviour, mood and functional capacity in the primary progressive aphasia variants. 62
34888957 2022

Variations for Aphasia

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

Pathways for Aphasia

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 10.31 APOE BDNF C9orf72 L1CAM LRRK2 MAPT
2 endosome GO:0005768 10.24 PSEN1 OPTN LRRK2 GRN C9orf72 APP
3 membrane raft GO:0045121 10.21 PSEN1 PRNP MAPT LRRK2 APP
4 neuron projection GO:0043005 10.15 APP C9orf72 CNKSR2 GRIN2A LRRK2 MAPT
5 synaptic vesicle GO:0008021 10.13 APP BDNF GRIN2A LRRK2 PSEN1
6 cell projection GO:0042995 10.11 SNCA PSEN1 NEFL MAPT LRRK2 L1CAM
7 synapse GO:0045202 10.1 SNCB SNCA PSEN1 LRRK2 GRIN2A C9orf72
8 neuronal cell body GO:0043025 10.06 APOE CNKSR2 L1CAM LRRK2 MAPT PSEN1
9 postsynapse GO:0098794 10.02 SNCA PSEN1 PRNP LRRK2 GRIN2A C9orf72
10 main axon GO:0044304 9.88 MAPT C9orf72 APP
11 inclusion body GO:0016234 9.86 SNCB SNCA PRNP LRRK2
12 axon GO:0030424 9.86 SNCA PSEN1 NEFL MAPT LRRK2 L1CAM
13 multivesicular body, internal vesicle GO:0097487 9.83 LRRK2 APOE
14 growth cone GO:0030426 9.44 SNCA PSEN1 NEFL MAPT LRRK2 L1CAM

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.34 APOE APP MAPT PSEN1 TARDBP TBK1
2 neuron projection development GO:0031175 10.24 MAPT L1CAM APP APOE
3 regulation of gene expression GO:0010468 10.23 TBK1 TARDBP PSEN1 LRRK2 APP APOE
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.21 TBK1 SNCA BDNF APP
5 memory GO:0007613 10.2 PSEN1 MAPT GRIN2A BDNF
6 neuron apoptotic process GO:0051402 10.19 SNCB SNCA PSEN1 APP
7 response to oxidative stress GO:0006979 10.16 APOE APP LRRK2 PRNP PSEN1
8 regulation of synaptic plasticity GO:0048167 10.14 PSEN1 MAPT GRIN2A
9 positive regulation of neuron death GO:1901216 10.11 SNCA PRNP MAPT
10 microglial cell activation GO:0001774 10.1 APP MAPT SNCA
11 cellular response to copper ion GO:0071280 10.09 APP PRNP SNCA
12 negative regulation of protein phosphorylation GO:0001933 10.09 TARDBP PSEN1 PRNP LRRK2 C9orf72
13 negative regulation of neuron apoptotic process GO:0043524 10.03 APOE BDNF GRN PSEN1 SNCA SNCB
14 cellular response to amyloid-beta GO:1904646 10.02 PSEN1 PRNP GRIN2A APP
15 learning or memory GO:0007611 10.02 PSEN1 PRNP MAPT GRIN2A APP
16 astrocyte activation GO:0048143 10.01 PSEN1 MAPT APP
17 amyloid fibril formation GO:1990000 10.01 APP MAPT SNCA TARDBP
18 regulation of neuronal synaptic plasticity GO:0048168 10 SNCA GRIN2A APOE
19 negative regulation of long-term synaptic potentiation GO:1900272 10 PRNP APP APOE
20 cellular response to manganese ion GO:0071287 9.97 LRRK2 APP
21 axon development GO:0061564 9.97 NEFL MAPT L1CAM
22 neuron projection maintenance GO:1990535 9.97 PSEN1 PRNP APP
23 positive regulation of xenophagy GO:1904417 9.96 TBK1 OPTN
24 regulation of mitochondrial fission GO:0090140 9.96 MAPT LRRK2
25 regulation of locomotion GO:0040012 9.95 LRRK2 SNCA
26 intracellular distribution of mitochondria GO:0048312 9.95 LRRK2 MAPT
27 dopamine metabolic process GO:0042417 9.95 SNCB SNCA GRIN2A
28 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.89 APP PSEN1
29 locomotion GO:0040011 9.85 PSEN1 NEFL GRIN2A
30 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.8 PSEN1 APP
31 positive regulation of amyloid fibril formation GO:1905908 9.8 PSEN1 APP APOE
32 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.64 APP PSEN1
33 astrocyte activation involved in immune response GO:0002265 9.63 PSEN1 GRN APP
34 regulation of neuron death GO:1901214 9.56 TBK1 SNCB SNCA LRRK2
35 synapse organization GO:0050808 9.4 SNCB SNCA PSEN1 MAPT L1CAM APP

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 TBK1 TARDBP SNCA PRNP OPTN NEFL
2 lipoprotein particle binding GO:0071813 9.46 MAPT APOE
3 cuprous ion binding GO:1903136 9.43 SNCB SNCA PRNP

Sources for Aphasia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....